Improvement of the robustness of the purification process of the intravenous immunoglobulin product (10%) Gammagard Liquid/Kiovig
|
|
- Cory Dawson
- 6 years ago
- Views:
Transcription
1 Improvement of the robustness of the purification process of the intravenous immunoglobulin product (10%) Gammagard Liquid/Kiovig Baxter BioScience F. Hupet, E. Felix, J. Van Malleghem, D. Delplace, C. Carnewal, E. Foy Presenter(s), Arial 18pt Gray Title/Function/Business Plasma Product Biotechnology Meeting 2011 Session: Manufacturing Perspectives 5/16/2011 1
2 Gammagard Liquid/Kiovig - Process robustness Outline Background Methodologies and tools (macro vs. micro approach) Improvement of process robustness: examples Challenges and risks Benefits 5/16/2011 2
3 Background Gammagard Liquid/Kiovig Immune Globulin Intravenous sterile solution (Human), 10% (w/v) Vial size: grams. Launch in 2005 (US) and 2006 (EU) Manufacturing facilities: Fractionation (LA, Rieti, Vienna) Purification (Lessines - Belgium) 5/16/2011 3
4 Background Process Robustness The ability of a manufacturing process to tolerate the expected variability of raw materials, operating conditions, process equipment, environmental conditions and human factors is referred to as process robustness (PQRI White Paper) Firms have to strive for the implementation of robust manufacturing processes that reliably produce pharmaceuticals of high quality and that accommodate process changes to support continuous process improvement (FDA report Pharmaceutical cgmps for the 21th Century A Risk-Based Approach) The system for robustness begins in R&D at the design phase of the process and goes on all along the product life cycle (scale-up, commercialization, postcommercialization). The scope of this presentation is the improvement of the process robustness during the post-commercialization phase of Gammagard Liquid/Kiovig. 5/16/2011 4
5 Methodologies and tools FMEA vs. DDFP Two complementary methodologies were and are used to improve the robustness of the Gammagard Liquid/Kiovig downstream process: 1. FMEA (Failure Modes and Effects Analysis) Macroscopic approach Risk identification & reduction 2. DDFP (Developing Defect Free Process) Microscopic approach Robust process 5/16/2011 5
6 Tools and methodologies FMEA (Failure Mode and Effects Analysis) FMEA is a widely known and used methodology. It is out of scope to give a detailed overview of the FMEA methodology; yet we remind here below the main steps: Review the process; Brainstorm potential failure modes and list the effects; Assign severity, occurrence and detection rankings; Calculate RPN; Develop the action plan and implement actions; Reassess the RPN after implementation of the actions. 5/16/2011 6
7 Tools and methodologies FMEA (Failure Mode and Effects Analysis) Gained experience from our FMEA performed on the Gammagard Liquid/Kiovig process: Due to the complexity and scale of manufacturing process, it is not practical to perform an FMEA on the whole process at the same time. The first process steps to be investigated have to be selected based on: Preliminary screening of the process steps using a matrix of scoring (# of failures, compliance risk,.); Major exceptions or recurrent issues for some steps; Process step impacted by a change (FMEA requirement is incorporated into the Change Control system). 5/16/2011 7
8 Tools and methodologies FMEA The team to be setup must be cross-functional and multi-disciplinary. It is a key element for successful FMEA. The absence of one or more services in the FMEA workshop can reduce its efficiency, and result in unrepresentative scoring. When starting a new working group, it can be useful to have a facilitator (e.g. Black Belt) in order to ensure that the methodology is applied objectively ; Manufacturing Engineering Technical Services FMEA Quality in Operations IT (Automation) Quality Engineering For an effective brainstorming, bring and use the relevant documents: Process narrative, In-Process Controls, P&ID, validation reports, database of exceptions, process flow charts, R&D development reports ; 5/16/2011 8
9 Tools and methodologies FMEA The scale for severity, occurrence and detection has to be clearly defined and well understood by the team. Two considerations: Limiting the number of scores eases the discussions. The magnitude between the lowest and the highest score values helps at differentiating between high and low priority risks. Example of scale used for Gammagard Liquid/Kiovig: 5/16/2011 9
10 Tools and methodologies FMEA Dedicate as much time as possible to the brainstorming session for the identification of failure modes. Do not adopt the This can never happen attitude; For major potential failures identified, go through the whole process to see if they may also happen at other manufacturing steps; The selection of the actions must favor preventing the error (elimination, replacement, mitigation) rather than minimizing the effects of the failure (detection, mitigation); Increasing robustness in a pharmaceutical process may take some time. Make manufacturing people aware of the risk if the implementation of related actions takes a long time; Frequency of FMEA workshops is typically ~3 per year (for a manufacturing process as Gammagard Liquid/Kiovig). Complete the implementation of the actions related to the identified risks before launching a new FMEA. 5/16/
11 Tools and methodologies FMEA Some process steps may present similarities between different products (e.g. nanofiltration). For those steps, there is a lot of added value in adopting a transversal approach (FMEA for a specific process step that is common to different products). Baxter Bioscience has recently applied this transversal FMEA approach for the viral inactivation steps of its products. Gammagard Liquid Gammagard SD Hemofil-M Advate Aralast Immunate SD Subcuvia S/D Treatment FMEA with an interfacility team of experts 11
12 Tools and methodologies DDFP (Developing Defect Free Process) What has driven the launch of this initiative? Experience from on-the-floor observations reveals that: People rarely challenge the status quo: We ve always done it that way ; I was told to do it that way. By nature humans will adapt to issues rather than address them: I have no authority to change that ; It takes less effort to go around the issue than to address it ; People have a limited understanding of their job: I don t know exactly why what I m doing is important 5/16/
13 Tools and methodologies Slide not distributed. 5/16/
14 Tools and methodologies Slide not distributed. 5/16/
15 Examples of Process Robustness Improvements FMEA - Example Improvement of the robustness of the glycine dialysis buffer preparation Glycine buffer preparation (original situation in 2006 RNP=729): Manufacturing runsheets: WFI addition in buffer tank: simple check Calculation for the amount of glycine to use: simple check Addition of glycine and final addition of WFI: double check ph adjustment of the glycine buffer: simple check Automation: No defined sequence for the buffer preparation; Workflow for supervision system commands unsecured in ifix user interface. 5/16/
16 Examples of Process Robustness Improvements Improvement of the robustness of the glycine dialysis buffer preparation Current situation after implementation of robustness actions (RPN=9): Manufacturing runsheets: Fixed amount of glycine to be added (no calculations) : simple check Conductivity and ph measurements of the buffer + check of the values vs. ranges (before ph adjustement): double check ph measurement before use of buffer: simple check Automation: Well-defined sequence (see next slide); At each sub-process step, critical parameters (ph, conductivity, mixing speed ) are automatically checked by the system; if not satisfactory, the buffer preparation cannot move to the next step; «Release» of the glycine buffer when completed. 5/16/
17 Examples of Process Robustness Improvements ifix user interface for dialysis buffer Slide not distributed. 5/16/
18 Examples of Process Robustness Improvements FMEA Additional examples of robustness Integrity test for CUNO setups; Reconcialiation calculation for the S/D preparation; Securing chronological sequences of the chromatographic sub-steps; Additional back-up for some critical samples; Maximum CM elution volumes; Securing opening of bottom valve for protein tanks; Range for the protein solution volume during dialysis; Most of the robustness improvements implemented in the frame of FMEA are based on automation and batch records modifications. 5/16/
19 Examples of Process Robustness Improvements DDFP - Example CIP Station: standardization of usage and change of HAc drums Slide not distributed. 5/16/2011
20 Examples of Process Robustness Improvements CIP Station: mistake proofing Slide not distributed. 5/16/
21 Examples of Process Robustness Improvements CIP Station: standardization of usage and change of HAc drums Slide not distributed. 5/16/
22 Examples of Process Robustness Improvements DDFP Slide not distributed. 5/16/
23 Examples of Process Robustness Improvements Additional examples of topics for DDFP workshop ph adjustement of CM eluate; Recovery of protein solution after filtration steps; Preparation of PptG (from freezer to process room); Preparation of SD components; Calibration of ph-meter 5/16/
24 Challenges/risks Increasing the robustness of a process may lead in some cases to unexpected process deviations (e.g. too tight range defined for buffer preparation). You need to find the right balance between increasing robustness and over-constraining the process; All potential failure modes cannot be identified during FMEA, especially those that would arise from combined failures; FMEA may lead to the identification of «gaps» (needs to be quickly corrected and possibly reported to Regulatory Agencies); Documentation of FMEA needs to be properly done, at least for those which have high visibility (e.g. for Change Control); Outputs from DDFP have to be incorporated into existing Quality systems. 5/16/
25 Benefits FMEA & DDFP: Increased process understanding; Quality improvement & cost reduction (reduced % of lot discarded); FMEA: Catalyst for teamwork and idea exchange between functions; Provide new ideas for improvement in similar design or processes; DDFP: People development; Defined robust best manufacturing sequences; Answer the question «How can we bring continuous improvement on the shopfloor». 5/16/
A dedicated DSP plant for the production of ClairYg, a LFB liquid Immunoglobulin G preparation for intravenous use
A dedicated DSP plant for the production of ClairYg, a LFB liquid Immunoglobulin G preparation for intravenous use Christophe SEGARD Technical Director Industrial Exploitation LFB 1 1 Objectives of a new
More informationSterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM
Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management Overview Key Regulatory
More informationHow to reach high plasma protein concentration with Single-Pass TFF: A case study from Baxter and
How to reach high plasma protein concentration with Single-Pass TFF: A case study from Baxter and Merck Millipore Eric Youssef Asia and Europe Plasma Market Lead Merck Millipore Bioplasma World Asia 2014
More informationAvoiding the Most Frequent Joint Commission Laboratory Survey Findings using Robust Process Improvement Tools (RPI) AVOIDING THE MOST
Avoiding the Most Frequent Joint Commission Laboratory Survey Findings using Robust Process Improvement Tools (RPI) AVOIDING THE MOST FREQUENT JOINT COMMISSION LABORATORY SURVEY FINDINGS USING ROBUST PROCESS
More informationThe Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics
The Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics Visit of Alabama Biotech Oct 2014 Alain BERNARD Vice President GPS, UCB Technical Operations Tech Ops BioTech
More informationProcess Risk through Application of FMEA. A Case Study. INTERPHEX March 17, 2009
Managing Process Risk through Application of FMEA to Batch Records A Case Study INTERPHEX March 17, 2009 Jon Hardy Lonza Head of Operations Hopkinton, MA Fred Greulich Maxiom Consulting Group, Inc. Director
More informationIdentification and Control of Critical Process Points Using Complementary Risk Assessments (corrected)
Identification and Control of Critical Process Points Using Complementary Risk Assessments (corrected) Karen McCullough MMI Associates (908) 534-6463 PDA Metro Chapter Day June 2, 2009 RISK is a four letter
More informationApplication of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols
Joint BWP/QWP/GMDP IWG Industry European Workshop on Lifecycle Management Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols 1 Outline Introduction: evolution of PACMP
More informationWhite Paper. Risk Management in Environmental Monitoring: Should you be spotting it sooner?
White Paper Risk Management in Environmental Monitoring: Should you be spotting it sooner? Executive Overview Quality Risk Management is a comparatively new approach in the pharmaceutical manufacturing
More informationParadigm Change in Manufacturing Operations SM
Technical Report No. 54-3 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 2: Case Studies in the Manufacturing of Pharmaceutical Drug Products
More informationA CHECKLIST FOR QUALITY. Seven Questions to Gauge Quality in Metal Stamping Suppliers
A CHECKLIST FOR QUALITY Seven Questions to Gauge Quality in Metal Stamping Suppliers The Value of Quality Quality. It s the #1 concern for OEM engineering and purchasing managers when evaluating and measuring
More informationWelcome Biotech 101. Outline. Before the Floor. Manufacturing Process. Supporting Cast 4/22/2013
Welcome Biotech 101 Outline Before the Floor All the activities that happen before large scale cgmp manufacturing Manufacturing Process Manufacturing steps Equipment Requirements How it all works together
More informationA Case Study on the Application of Disposable Technologies in cgmp Manufacturing Processes for a Therapeutic Antibody.
A Case Study on the Application of Disposable Technologies in cgmp Manufacturing Processes for a Therapeutic Antibody. Jeremy M Tong (presenting), Mark S Kettel, Edward M Perry, David J Pain, David M Valentine,
More informationNovel Technologies in Plasma Fractionation. Dieter Fassnacht
Novel Technologies in Plasma Fractionation Dieter Fassnacht Agenda Grifols Overview Grifols Engineering Innovations in - Pooling - Fractionation - Filling Developing new technologies to provide innovative
More informationChapter 6-1: Failure Modes Effect Analysis (FMCEA)
Chapter 6-1: Failure Modes Effect Analysis (FMCEA) Learning Outcomes: After careful studying this lecture You should be able: To Define FMEA To understand the use of Failure Modes Effect Analysis (FMEA)
More informationContinuous Purity Technological, Regulatory and Validation Considerations for single-use continuous downstream processing
Marc Bisschops Tarpon Biosystems Inc. Continuous Purity Technological, Regulatory and Validation Considerations for single-use continuous downstream processing Integrated Continuous Biomanufacturing Castelldefels
More informationENGINEERING CHALLENGES FROM THE LAB TO FACILITY
ENGINEERING CHALLENGES IN SCALING PURIFICATION FROM THE LAB TO FACILITY Christian Lim, Process Engineer CRB (Clark, Richardson, & Biskup) Consulting Engineers Boston, MA 10-May-2012 Topics Introduction
More information510(k) Summary. 510(k) Number: K Summary Prepared: August 31, 2017
510(k) Summary 510(k) Number: K162613 Summary Prepared: August 31, 2017 Submitter: Dr. Fred Ma Repro Med System, Inc., D/B/A RMS Medical Products 24 Carpenter Road, Chester, NY 10918 Tel: 845-469-2042
More informationPlasma Fractionation Today and in the Future Plasma Product Biotechnology Meeting
Plasma Fractionation Today and in the Future 2013 Plasma Product Biotechnology Meeting 1 What we do matters Dayna and her husband, Brian, are the parents of four wonderful, amazing children, Charlie, Kate,
More informationIntegrated Process Engineers & Constructors, Inc.
Integrated Process Engineers & Constructors, Inc. CORPORATE MISSION STATEMENT IPEC provides design, engineering, project management, fabrication, installation services and prepackaged modular systems through
More informationFailure Mode Analysis and How It Impacts Your Strategy
Failure Mode Analysis and How It Impacts Your Strategy Helen Ramsey, National Asset Manager Utility Services, Downer, Auckland Abstract Asset owners want to clearly understand what drives reactive expenditure
More informationDynamic Core with Mimic
Dynamic Core with Mimic Introduction Dynamic Core is a unique approach to delivering dynamic simulations for operator training and control system testing. This method of modeling delivers a medium fidelity
More informationApplication of Disposable Technologies in Biopharmaceutical Manufacturing
BMD Summit, Disposables for Biopharm Production 13th December 2005 Reston, VA, USA Application of Disposable Technologies in Biopharmaceutical Manufacturing Martin Wrankmore, Continuous Improvement Lead,
More informationContents of the Failure Mode Effects Analysis the Plant Wellness Way Distance Education Course FMEA Training Online
Contents of the Failure Mode Effects Analysis the Plant Wellness Way Distance Education Course FMEA Training Online Use the FMEA process in your plant and equipment design, and for root cause analysis
More informationConsiderations for Implementation of Single-Use Technologies in Bioprocessing. Guido Kremer-van der Kamp Merck Millipore
Considerations for Implementation of Single-Use Technologies in Bioprocessing Guido Kremer-van der Kamp Merck Millipore Single-Use Technologies in Bioprocessing Adoption of single-use technologies in biopharmaceutical
More informationParadigm Change in Manufacturing Operations
Technical Report No. 54-4 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 3: Case Studies in the Manufacturing of Biotechnological Bulk Drug
More informationIntegrated Quality Systems
Integrated Quality Systems Introduction THE PRODUCT IQS provides a powerful and proven solution that offers a unique model for integrating quality systems to achieve superior enterprise-wide performance.
More informationAbstract. This guide discusses how Helix ALM simplifies the FMEA process and makes them more visible early in the development process.
Abstract Failure modes and effects analysis (FMEA) helps companies discover the risks that could occur with a product both built-in risks and issues that might arise because of the way users interact with
More informationKeeping ahead in biopharmaceutical manufacturing
Keeping ahead in biopharmaceutical manufacturing Bioprocessing Network Annual Conference 2009 1 st October 2009 Dr Owen Tatford Process Development Manager May 2009 Biostate Process Overview 1 Introduction
More informationThe validation of biological Active Pharmaceutical
This article presents a procedure for the validation of biological API manufacturing processes. It details each step of the procedure for biological processes applications, and covers the regulatory requirements
More informationHow single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs
WHITE PAPER 7004 How single-use connections advance aseptic processing: Increased process flexibility and reliability, reduced costs By John Boehm Business Unit Manager Colder Products Company Today s
More informationQCL and DSS Training For Suppliers. May 4, 2016
QCL and DSS Training For Suppliers May 4, 2016 Training Agenda 1. Introduction to Nexteer Engineering Procedure G1331 2. DSS Assessment & Control Level Charts 3. DFMEA / DSS / PFMEA / PCP 4. Alternative
More informationControlling Agilent 1200 Series Rapid Resolution LC systems through Waters Empower chromatography data software. Technical Overview.
Controlling Agilent 1200 Series Rapid Resolution LC systems through Waters Empower chromatography data software Technical Overview Abstract The Waters Empower 2 chromatography data software with ICS 1.05
More informationCleaning Validation in a Biologics Facility Case Study. CBE Pty Ltd
Cleaning Validation in a Biologics Facility Case Study CBE Pty Ltd This training program is copyright to CBE Pty Ltd and may not be modified, reproduced, sold, loaned, hired or traded in any form without
More informationContact details: Anna Silvani
Consultation Document Good Manufacturing Practice for Advanced Therapy Medicinal Products MolMed comments to the DG SANTE consultation on GMPs for ATMPs pursuant to Article 5 of Regulation 1394/2007. MolMed
More informationSTRATEGIES FOR CLEANING
STRATEGIES FOR CLEANING AND CLEANING VALIDATION THAT MINIMIZE DOWNTIME FOR PRODUCT CHANGEOVERS JOHN HYDE HYDE ENGINEERING + CONSULTING PRESENTATION OUTLINE Importance of Cleaning Process Development at
More informationOver the past five to ten
B IOP ROCESSTECHNICAL Characteristics of a Good Antibody Manufacturing Process Bradley Wolk, Paul Bezy, Ray Arnold, and Greg Blank Over the past five to ten years, manufacturing of antibodies for use as
More informationLeveraging an EA for an Integrated Platform in Life Sciences. Cop yri g h t 2014 OSIso f t, LLC.
Leveraging an EA for an Integrated Platform in Life Sciences Presented by Axel Schnuetgen Business Overview Healthcare Corp Baxter BioScience Baxter Medical Products Baxter's BioScience business continues
More informationEden Approach To Bioprocess Characterisation. Philip Mellors p USP Development & Transfer Team Leader
Eden Approach To Bioprocess Characterisation Philip Mellors p USP Development & Transfer Team Leader Process Characterisation What is Process Characterisation? A late stage study that evaluates the process
More informationFOR RESEARCH USE ONLY. NOT FOR HUMAN OR DIAGNOSTIC USE.
User Protocol 122643 Rev. 12 May 2005 JSW Page 1 of 7 ProteoExtract Albumin/IgG Removal Kit, Maxi Cat. No. 122643 1. Introduction One of the major challenges in functional proteomics is the handling of
More informationSolving Tech Transfer Challenges for Complex Pharmaceutical Products
Solving Tech Transfer Challenges for Complex Pharmaceutical Products Edwin HOPPENBROUWERS Director New Product Introduction Catalent Pharma Solutions 26.11.2011 PROJECT Product information Natural protein
More informationScientific Considerations for Continuous API Manufacturing
Scientific Considerations for Continuous API Manufacturing Thomas O Connor, Ph.D. Office of Pharmaceutical Quality/Office of Testing and Research US FDA Center for Drug Evaluation and Research FDA PQRI
More informationINTRODUCTION TO FMS. Type of Automation. 1. Fixed automation 2. Programmable automation 3. Flexible automation Fixed Automation
Type of Automation 1. Fixed automation 2. Programmable automation 3. Flexible automation Fixed Automation INTRODUCTION TO FMS Sequence of processing (or assembly) operations is fixed by the equipment configuration
More informationFMEA Failure Mode Effects Analysis. ASQ/APICS Joint Meeting May 10, 2017
FMEA Failure Mode Effects Analysis ASQ/APICS Joint Meeting May 10, 2017 FMEA (Failure Mode and Effects Analysis) Failure Mode and Effects Analysis Agenda What is it? Motivation FMEA Methods Examples What
More informationCleaning Validation Systems CIP COP Manual How to get to Validation
Cleaning Validation Systems CIP COP Manual How to get to Validation First: Know and Understand the Soils and Residues You Must Clean Virus 3 Raw Meat and Prions 4 Formalin Sodium Citrate Sucrose Triton
More informationA CHECKLIST FOR QUALITY. Seven Questions to Gauge Quality in Metal Stamping Suppliers
A CHECKLIST FOR QUALITY Seven Questions to Gauge Quality in Metal Stamping Suppliers The Value of Quality Quality. It s the #1 concern for OEM engineering and purchasing managers when evaluating and measuring
More informationMonTech RP 3000 Rapid Plastimeter for Polymers and Natural Rubber
Plasticity 02 MonTech RP 3000 Rapid Plastimeter for Polymers and Natural Rubber The MonTech Rapid Plastimeter measures the plasticity or viscosity of polymers and unvulcanised rubbers. The test is simple,
More informationLG SOURCING VENDOR QUALITY MANAGEMENT SYSTEM REQUIREMENTS
LG SOURCING VENDOR QUALITY MANAGEMENT SYSTEM REQUIREMENTS LG Sourcing QMS ver01 03.29.2010 Page 1 of 16 PAGE INTENTIONALLY LEFT BLANK Copyright 2010, LF Corporation - All rights reserved No part of this
More informationCOMPARISON OF PROCESS HAZARD ANALYSIS (PHA) METHODS
COMPARISON OF PROCESS HAZARD ANALYSIS (PHA) METHODS by Primatech Inc. The hazard and operability (HAZOP) study is the most commonly used process hazard analysis (PHA) method. However, there are many other
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More information6 Steps to Designing a Flexible Control System with ISA-88. Quality, Experience, and Peace of Mind: Cross Company Process Control Integration
6 Steps to Designing a Flexible Control System with ISA-88 Quality, Experience, and Peace of Mind: Cross Company Process Control Integration 6 Steps to Designing a Flexible Control System with ISA-88 US
More informationRecent Developments & Future Directions in the Production of Monoclonal Antibodies. Rob Noel Plasma Product Biotechnology Conference 2009, Menorca
Recent Developments & Future Directions in the Production of Monoclonal Antibodies Rob Noel Plasma Product Biotechnology Conference 2009, Menorca Forecast sales by molecule type ($m), 2006 12 600,000 Pharmaceuticals
More informationImplement Effective Computer System Validation. Noelia Ortiz, MME, CSSGB, CQA
Implement Effective Computer System Validation Noelia Ortiz, MME, CSSGB, CQA Session Outline 1 2 3 4 5 Understanding Regulations and Guidelines Pertaining to Computer Systems Integrate SDLC and GAMP 5
More informationRisk Based Validation. Why, How and with what tools?
Risk Based Validation Why, How and with what tools? Tech Talk Agenda History of FDA GMP initiative for the 21 st Century. Industry response to FDA initiative. Harmonisation through ICH. ASTM Standard on
More informationBiologics. Biologics. The Centre for Process Innovation. From innovation to commercialisation
Biologics Biologics The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The High Value Manufacturing Catapult is
More informationLeft to Our Own Devices Design Control & Risk Management Strategies for Combination Products
Left to Our Own Devices Design Control & Risk Management Strategies for Combination Products DR. RICK WEDGE 12 MAR 2018 Overview Definitions Current Regulatory Landscape Design Controls Risk Management
More informationLarge Scale Process Modules First in Place Technology. Detlef Kehm, PhD VP Site and Project Engineering April 24 th, 2013
Large Scale Process Modules First in Place Technology Detlef Kehm, PhD VP Site and Project Engineering April 24 th, 2013 Agenda Project Introduction Statistics, Design Objectives, Technology Considerations
More informationGood Engineering Practices: What Can We Learn from the Pharmaceutical Industry
Good Engineering Practices: What Can We Learn from the Pharmaceutical Industry ISA EXPO 2009 Standards Certification Education & Training Publishing Conferences & Exhibits Welcome Background George Buckbee,
More informationDeveloping the Control Strategy for Enhanced Testing and Continuous Monitoring
Developing the Strategy for Enhanced Testing and Continuous Monitoring i Graham Tulloch, PhD Research Advisor BioProcess Research and Development Outline Introduction Regulatory environment strategy t
More informationAutomated System Validation By: Daniel P. Olivier & Curtis M. Egan
Automated System Validation By: Daniel P. Olivier & Curtis M. Egan In today s technical environment validation practices are both a requirement and an important tool in the medical and pharmaceutical industry.
More informationTechnical Report No. 61 Steam In Place
Technical Report No. 61 Steam In Place PDA Technical Report No. 61: Steam in Place Task Force Members Authors Kevin Trupp (Task Force Chair), Retired Dave Adams, Baxter Healthcare Corporation Keith E.
More informationPlanova Virus Filtration Systems. Automated virus removal for clinical- to commercial-scale manufacturing
Planova Virus Filtration Systems Automated virus removal for clinical- to commercial-scale manufacturing Built For You. Asahi Kasei Bioprocess is dedicated to unlocking efficiencies and driving productivity
More informationProcess Systems M+W Process Industries GmbH
Process Systems M+W Process Industries GmbH Challenges in the Life Science Industry The manufacture of medicines in solid, semi-solid and liquid forms is a challenge for every pharmaceutical company. This
More informationVirus Safety in Plasma- Derived Therapeutics: A Merck Perspective. IPFA Yogyakarta, March Louis Wong
Virus Safety in Plasma- Derived Therapeutics: A Merck Perspective IPFA Yogyakarta, March 2017 Louis Wong Associate director, Plasma Initiative, Asia-Pacific Content Regulatory Expectations for Plasma-Derived
More informationBioprocess Chrom Systems
Bioprocess Chrom Systems Combining gradient and inline buffer dilution capability with powerful software to your specifications BPC BIC Equipment designed to respect your individual needs. 2 Built For
More informationIG Production and Safety
IG Production and Safety Platelet Disorder Support Association July 20, 2013 Mary Gustafson, Vice President, PPTA Global Regulatory Policy Presentation Outline Introduction - PPTA Plasma Collection Final
More informationHSE Design Reviews and Action Close-out
HSE Design Reviews and Action Close-out Simon Round, Manager Design HSE, Amec Foster Wheeler, Shinfield Park, Reading, Berkshire RG2 9FW, UK HSE design reviews and the management and close-out of resulting
More informationRisk Analysis: myths, confusions and real sense
Risk Analysis: myths, confusions and real sense Dr. Alexander Fedotov, Director of Invar-project Company, Moscow, Russia fedotov@invar-project.ru www.invar-project.ru 1. What is risk analysis? 2. GMP EU
More informationRisk Management ICH Q9 - FMEA - Applied to Validation
Risk Management ICH Q9 - FMEA - Applied to Validation PBE, Pharma Bio Expert Inc PBE-Expert Inc CANADA Training Company Agreement CPMT #0059104 Health Canada & expert, Training Company Agreement CPMT #0059104
More informationAutomating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper
Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper Varian, Inc. 2700 Mitchell Drive Walnut Creek, California 94598, USA www.varianinc.com Introduction Chromatographic
More informationToray Plastics (America), Inc. Optimizes Manufacturing Operational Performance with Big Data Analytics
Toray Plastics (America), Inc. Optimizes Manufacturing Operational Performance with Big Data Analytics Background If you ve ever indulged in a bag of chips or munched on a breakfast cereal bar, then you
More informationViral Clearance Studies
Viral Clearance Studies viral clearance studies from the industry leader with unmatched experience and expertise Viral clearance is a critical component of regulatory submissions as it helps demonstrate
More informationGoing Paperless Baxter MD - Full electronic Batch Record & Release with XFP SIMATIC IT. Answers for industry.
Going Paperless Baxter MD - Full electronic Batch Record & Release with XFP SIMATIC IT Answers for industry. Before we implemented XFP-MES at the Irish plant, the documentation department needed 3 to 4
More informationLessons from Pharmaceutical Laboratory related FDA Warning Letters
Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance
More informationAutomated Purification Software for Agilent OpenLAB CDS
Automated Purification Software for Agilent OpenLAB CDS Data Sheet Introduction Agilent 1260 Infinity LC and LC/MS purification systems offer flexible and easy to use solutions for purification of microgram
More informationTesting in Design. James Huff
Testing in Design James Huff Learning Objectives At the end of this session, you will be able to: 1. Describe at least three ways to test your projects 2. Describe how prototypes can be used in testing
More informationOnline Course Manual By Craig Pence. Module 12
Online Course Manual By Craig Pence Copyright Notice. Each module of the course manual may be viewed online, saved to disk, or printed (each is composed of 10 to 15 printed pages of text) by students enrolled
More informationValidation of Pharmaceutical Manufacturing Process Focus: APIs.
Validation of Pharmaceutical Manufacturing Process Focus: APIs Validations: Regulatory History (US FDA) Sterilisation 1977 Aseptic processing 1979 Water Systems 1981 Non-sterile Mfg Process 1987 Revised
More informationAutomating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper
Automating HPLC and GC Analytical Method Validation Fusion AE Software Program White Paper S-Matrix Corporation 1594 Myrtle Avenue Eureka, CA 95501, USA www.smatrix.com Introduction Chromatographic analytical
More informationFacility Optimization A Facility Team Perspective Mike St. Louis VP Operations Critical Process System Group 19Feb15
Facility Optimization A Facility Team Perspective Mike St. Louis VP Operations Critical Process System Group 19Feb15 Facility Optimization What is it? What is an Optimal Facility? Depending on who you
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationRiskyProject Lite 7. Getting Started Guide. Intaver Institute Inc. Project Risk Management Software.
RiskyProject Lite 7 Project Risk Management Software Getting Started Guide Intaver Institute Inc. www.intaver.com email: info@intaver.com Chapter 1: Introduction to RiskyProject 3 What is RiskyProject?
More informationManaging Risk IGMA Winter Conference Tucson, Arizona Feb 1, 2018
Managing Risk IGMA Winter Conference Tucson, Arizona Feb 1, 2018 this workshop was brought to you by www.human.ca 1 What is Risk and why should we be interested in it? Risk refers to the uncertainty that
More informationTransferring a process to a contract
Reprinted from PHARMACEUTICAL ENGINEERING The Official Magazine of ISPE July/August 2010, Vol. 30 No. 4 www.ispe.org Copyright ISPE 2010 This article presents a process transfer case study and the significance
More informationQuality Management Systems How ISO Processes Can Power Your Business Management System
Quality Management Systems How ISO Processes Can Power Your Business Management System June 12, 2013 Helping Manufacturing Enterprises Grow Profitably Session Objectives What s the benefit of a QMS? What
More informationSEMBIT SQA Unit Code F9HK 04 Applying failure modes and effects analysis (FMEA)
Overview This unit covers the competences required for applying failure modes and effects analysis (FMEA). It involves applying the principles and processes of FMEA and determining the key features of
More information2. Risk-based compliance was also a key component in the FDA's new approach for dealing with electronic records and signatures: 21 CFR Part 11.
LITERATURE REVIEW: Risk management is well known and practiced in many industries and several industry task forces have developed guidance documents that facilitate risk management. Risk management for
More informationContinuous Improvement of Prothrombinex-VF Manufacture
Continuous Improvement of Prothrombinex-VF Manufacture Owen Tatford Process Development Manager and John Lontos Fractionation Manager BPN Conference, Adelaide 2011 Prothrombinex-VF (PTX) A Prothrombin
More informationIng.-Büro Pfeufer. FMEA Alignment AIAG and VDA. Join the conversation: #AQMS2018 VDA QMC
Ing.-Büro Pfeufer New Your global Workshop FMEA Title standard Goes Here FMEA Alignment AIAG and VDA Join the conversation: #AQMS2018 Status November 2018 FMEA Alignment AIAG and VDA Project Leader: AIAG:
More informationCould Poor Temperature Data Management be Putting Your GxP Facility at Risk for Data Integrity Violations? we prove it.
1 How to Meet New MHRA, FDA and WHO Data Integrity Guidelines WHITE PAPER Could Poor Temperature Data Management be Putting Your GxP Facility at Risk for Data Integrity Violations? we prove it. 2 How to
More informationTechnical Note. Introduction
Online HPLC for Biotechnology: Groton Biosystems Automated Reactor Sampling System and Agilent 1200 Series LC System Technical Note Introduction Online analytical instrumentation facilitates productive,
More informationOverview Rentschler Biotechnologie
Overview Rentschler Biotechnologie AusBiotech, Adelaide, 18.10.2011 Klaus B. Schoepe, PhD, SVP Client Relations - 1 - Our Mission As an independent leading, internationally operating service company, we
More informationIncremental GMPs. Presented by: Karen S. Ginsbury For: IFF October 31, Nov 02, PCI Pharmaceutical Consulting Israel Ltd.
Incremental GMPs Presented by: Karen S. Ginsbury For: IFF October 31, Nov 02, 2017 1/55 Sound Science Good Development Practice Traceability R&D Tox I II III IV What You Need Here Can t be generated here
More informationQuality by Design for Legacy Products A Contradiction?
Quality by Design for Legacy Products A Contradiction? Qualification and Verification of Manufacturing Process throughout the Product Life Cycle Dr. Joerg Gampfer WCBP 2015- CASSS Conference Washington
More informationCurriculum Vitae Dr. Gunther Roiss
Curriculum Vitae Dr. Gunther Roiss Surname First name Place of residence Roiss Gunther Zurcherstrasse 11, CH-4332 Stein Date of birth 12.03.1970 Civil status Nationality Divorced, no children Austria Phone
More informationMovicon in the food industry: The dairy production plant at Parmareggio
Movicon in the food industry: The dairy production plant at Parmareggio The Parmareggio Unigrana creameries produce butter using top quality raw materials from the famous region of Parmigiano Reggiano.
More informationUse of Fluidised bed chromatography for plasma fractionation. Karl McCann*, John Wu, Peter Gomme & Joseph Bertolini
Use of Fluidised bed chromatography for plasma fractionation Karl McCann*, John Wu, Peter Gomme & Joseph Bertolini Plasma Fractionation Industry Mature with well established processes Revenue growth -
More informationDelivering High-Impact Projects in an Operational Pharmaceutical Facility
Delivering High-Impact Projects in an Operational Pharmaceutical Facility This white paper identifies five ways to mitigate owner risk on construction projects completed within a fully operational pharmaceutical
More informationControl strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA
Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not
More informationMatching Flows: The Development of Continuous Manufacturing of Biotech Products
Matching Flows: The Development of Continuous Manufacturing of Biotech Products Jeffrey C. Baker, Ph.D. Deputy Director, Office of Biotechnology Products, CDER By telecon to ECI s Integrated Continuous
More information